Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Regorafenib Provides Modest Survival Benefit in Refractory Advanced Gastric/GEJ Cancer

November 4th 2024

Regorafenib improved overall survival vs placebo in refractory advanced gastric or gastroesophageal junction cancer.

SHR-A1921 Demonstrates Early Efficacy in Platinum-Resistant Ovarian Cancer

November 3rd 2024

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

November 1st 2024

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia

October 29th 2024

BGB-16673 had acceptable tolerability and showcased early antitumor activity in patients with relapsed/refractory Waldenström macroglobulinemia.

Empowering Community Cancer Care: Importance of Outreach Initiatives

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer.

Empowering Community Cancer Care: Survivorship and Support Programs

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources.

Empowering Community Cancer Care: Integrating Screening Programs

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, experts discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.

Empowering Community Cancer Care: Promoting Education

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr Woodworth discusses her outreach efforts in the Santa Clarita community, including partnering with organizations like the American Cancer Society, hosting educational panels for women, and providing continuing medical education for local physicians to ensure comprehensive cancer care and awareness.

Empowering Community Cancer Care: Importance of Collaboration

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

October 21st 2024

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Prophylactic Measures

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the need for continued evaluation of prophylactic treatments like tocilizumab and antimicrobial measures for bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Management Strategies

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Awareness of AEs

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Overview

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

October 21st 2024

The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.